INCB 24360-208 A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
July 13, 2018
End Date
August 23, 2019
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
July 13, 2018
End Date
August 23, 2019